TD Cowen Affirms Buy Rating on American Tower (AMT) with $241 PT, Citing Solid Demand
On June 5, TD Cowen analysts maintained a Buy recommendation on American Tower Corporation (NYSE:AMT) with a target price of $241, far surpassing present trading levels. The firm reiterated its confidence in AMT's growth trajectory, noting robust enterprise demand despite ongoing macroeconomic headwinds.
A wide angled view of a high-rise office building, the windows reflecting a nearby cityscape.
TD Cowen analysts observed that initial talks on tower densification have started, and demand for GenAI inference fiber might arise sooner than expected. American Tower Corporation (NYSE:AMT) management upheld its 2025 US leasing target of $165-170 million and signaled confidence in a 5% long-term growth rate.
American Tower forecasts roughly 4.3% in organic growth this year, with an expected boost to 5% in the coming years to fulfill its long-term growth objective. Management also projects a reduction in churn to the lower end of its average prior range of 1-2% as the last phase of Sprint churn finishes in Q3 of 2025.
AMT's management pointed out solid enterprise demand, commenting that average customers are now using their individual inference models. This transition from depending on hyperscalers to businesses managing their models presents considerable growth prospects because of the vast number of enterprise customers.
American Tower Corporation (NYSE:AMT) is one of the world's largest real estate investment trusts, known for owning and operating a major network of communications real estate.
While we acknowledge the potential of AMT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.
READ NEXT: and.
Disclosure: None.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Stillwater to treat water for PFAS with $2.5M temporary facility
Construction will begin this summer on a temporary solution to PFAS chemicals found in parts of Stillwater's water supply. Market and Johnson Inc., of Eau Claire, Wis., submitted the lowest bid to construct a temporary facility to treat water from one of Stillwater's wells to meet the latest standards for per- and polyfluoroalkyl substances, also known as 'forever chemicals' because they resist breaking down in the environment. Five bids were received and opened, city officials said. Market and Johnson, which has a local office in Stillwater, submitted a bid of $2,517,000, which beat the engineer's estimate of $2,678,000, city officials said. The Stillwater City Council voted June 3 to accept the bid. The facility, which will be located adjacent to Well No. 10 near Benson Park, is expected to be in operation until a permanent solution is found. The facility will use granulated activated carbon to treat the water. The city secured a $3 million grant from the Public Facilities Authority for construction of the temporary water treatment facility, said City Administrator Joe Kohlmann. Construction will begin this summer, and the facility should be operational by late 2025 or early 2026, he said. PFAS chemicals were found to have contaminated drinking water supplies in parts of the eastern Twin Cities, including in Stillwater's groundwater supply. 3M and other companies manufactured the substances for use in products ranging from nonstick cookware to firefighting foam, but now they have made their way into water and food supplies across the country and have been linked to cancers and other health issues. The Trump administration recently announced plans to relax limits on certain 'forever chemicals.' But for two commonly found types, PFOA and PFOS, the limits put in place by the Biden administration will remain in place. Utilities will have two more years — until 2031 — to meet them. Two wells in Stillwater – Well No. 6 and Well No. 10 – were found to contain PFAS at levels above health-based guidance values for drinking water. An additional well, Well No. 9, contains PFAS at levels just below these standards. All three wells are currently inactive and are not providing water for the community, Kohlmann said. The temporary treatment facility at Well No. 10 will ensure the well can safely be put back into service to meet drinking-water standards, he said. Driver, 23, dies in single-vehicle crash in Scandia Emaciated stowaway cat found in Minnesota after epic journey from China Stillwater: Lift Bridge rescue call was false alarm, authorities say East Metro Softball Player of the Year: Forest Lake's Avery Muellner Retiring Woodbury city administrator says over 21 years, he's watched the city grow
Yahoo
30 minutes ago
- Yahoo
On the Record: Federal funding cuts threaten 1/3 of WTVP budget
PEORIA, Ill. (WMBD) — Local PBS affiliate stations like WTVP are sounding the alarm for their future after the Trump administration formally requested Congress to claw back funding for the next two years. WTVP President and CEO Jenn Gordon joined 'On the Record' and said the cuts will have a devastating impact on her station, which has just recovered from a financial situation of its own. 'So we're looking at an impact of about a third of our annual funding being immediately cut, if this rescission package goes through. So a lot is at stake here. More than 1.3 million people have already contacted Congress to voice their support [for public media],' she said. Gordon emphasized that public media differs from commercial media in that it's a private-public partnership. 'We're nonprofit organizations that rely in part on federal support to offer commercial-free programming to everyone. It was set up originally to receive some taxpayer dollars to get the ball rolling, but then also all of our local stations, we do quite a bit of fundraising to supplement that,' said Gordon. That federal funding could disappear in less than two months. The Trump administration, on Tuesday, sent Congress a rescission package, formally requesting the return of $1.1 billion already allocated for fiscal years 2026 and 2027 to fund the Corporation for Public Broadcasting. That starts a countdown of 45 days for Congress to respond. If passed, Gordon said local stations like WTVP stand to lose nearly a third of their annual funding. 'This isn't just about national programming,' Gordon warned. 'Smaller stations will feel the cut even more sharply. At WTVP, we'd have to immediately shift into emergency fundraising mode to try to close the gap. It could slow or stop local and educational programming, and delay production for new shows.' The rescission package comes on the heels of another blow to public media. President Trump issued an executive order on May 1 to shut down PBS and NPR, citing bias and irrelevance. Both organizations have filed lawsuits in response, arguing the order is a violation of the First Amendment. Gordon said the ripple effects from the loss of funding will be felt everywhere, from fewer children's programs to potential job impacts at the local level. 'Some of that federal funding goes to actually producing programs. So you're going to see a shortening of production timelines. And then additionally, at the local level, it's going to immediately need us to move into a grassroots fundraising mode to try and make up for that difference,' she said. So, how can you help? Gordon said to call or send a message to your lawmakers voicing your support for public media. You can also visit 'It takes five minutes and could make a real difference,' she said. On June 3, PBS President and CEO Paula Kerger echoed Gordon's sentiments in a statement. 'The proposed rescissions would have a devastating impact on PBS member stations and the essential role they play in communities, particularly smaller and rural stations that rely on federal funding for a larger portion of their budgets,' she said. 'Without PBS member stations, Americans will lose unique local programming and emergency services in times of crisis. There's nothing more American than PBS, and we are proud to highlight real issues, individuals, and places that would otherwise be overlooked by commercial media.' PBS was created in by the Corporation for Public Broadcasting in 1969 to provide Americans with a non-commercial space for news, educational programming, and inspirational content. There are approximately 350 stations across the country. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
30 minutes ago
- Yahoo
Hims & Hers Stock Is Soaring Again. But Should You Buy the Stock?
Hims & Hers stock is on the upswing after the company secured a weight-loss drug partnership. Hims & Hers is acquiring its way into Europe and wants to build more personalized drugs for its telehealth customers. Shares have soared, but still have a ton of potential for patient long-term shareholders. 10 stocks we like better than Hims & Hers Health › Many companies have failed to disrupt the complicated U.S. healthcare market. Hims & Hers (NYSE: HIMS) may finally be succeeding in cracking the code. The online telehealth platform focuses on circumventing the insurance market; its business of selling affordable medications directly to individuals is growing like a weed, and expects to generate $6.5 billion in revenue by 2030. It has had a tumultuous start to 2025, as Hims & Hers waged a battle to sell new weight loss medications on its online marketplace. Now, with momentum back on its side, the stock is up 118% year to date and 446% in the last five years. Let's take a deeper look at this company, and see whether you might want to buy Hims & Hers stock for your portfolio now. Hims & Hers' model is simple. It has two separate web platforms -- Hims for men and Hers for women -- that sell medications and deliver to customers' front doors. It began with sexual health, but has moved into dermatology, hair loss, mental health, and now weight loss medications. A key to its success has been avoiding the insurance market with products that don't break the bank. Customers loathe dealing with health insurers in the United States, and sometimes would rather not use insurance at all. Plus, some of these products aren't covered by insurance. This strategy has helped the company close in on over $2 billion in projected revenue in 2025. To keep up this impressive growth, Hims & Hers wants to offer weight loss medications, which have been a blockbuster set of drugs for the pharmaceutical market. For a while the popularity of these drugs, such as Novo Nordisk's Wegovy, left them in short supply; that allowed third parties such as Hims & Hers to produce them as a compounding pharmacy and sell them at much cheaper prices. This ended up generating $200 million of Hims & Hers' $1.4 billion in 2024 revenue. But with the shortage of Wegovy over and the compounding pharmacy exception ended, the company's weight-loss business was at a major turning point. Luckily, at the end of April Hims & Hers announced a partnership with Novo Nordisk that seems to resolve this issue: It gives Hims & Hers the ability to sell Wegovy directly on its platform. Hims & Hers is not an exclusive supplier of the drug -- or any drugs on its marketplaces, to be fair -- but it hopes to use its subscription business model, marketing expertise, and simplified user proposition to drive sales for Novo Nordisk in the huge obesity-care market. Besides weight loss drugs, Hims & Hers has more ambitions to reach its goal of $6.5 billion in revenue by 2030. Just recently, the company announced its intent to acquire European competitor Zava so it could expand its telehealth service to Europe. The acquisition will add a platform with 1.3 million active customers in the U.K., Germany, France, and Ireland. It makes sense that Hims & Hers can supercharge growth for the platform with its plethora of medications offered to customers, keen marketing skills, and subscription-based selling model. Over the long run, Hims & Hers aims to make healthcare for its customers more personalized. This includes unique drug combinations, its own outsourcing facility, and at-home testing capabilities. Details remain sparse, but the vision is clear: disrupting more and more of the trillions of dollars spent on healthcare by building a business that people actually enjoy interacting with. This is why 2.4 million active customers use Hims & Hers today. A revenue goal of $6.5 billion seems well within reach by 2030. Hims & Hers is only at 2.4 million active customers, and there are tens of millions of people in the United States alone who could start using or switch to one of its telehealth platforms. Add on the Zava acquisition in Europe, and the runway for growth gets even larger. The company has an impressive gross profit margin of 77%, which should lead to high levels of profitability at scale. On $6.5 billion in future revenue, it could very well post a net profit margin of over 20%, and achieve $1.5 billion in bottom-line profits and free cash flow. A 20% profit margin is easily achievable because of its high gross margins and the fact it currently spends 40% of revenue on marketing today, a figure that has come down over time and should come down even more as Hims & Hers keeps scaling. However, Hims & Hers has played fast and loose with laws and regulations in the past. It sold weight loss drugs when the legality of doing so was unclear, and although that dispute seems to have been resolved, management could easily start playing with fire again and burn its reputation as a trusted provider of medications. Otherwise, this looks like a fantastic growth stock that just doubled its addressable market with the Zava acquisition. Today, Hims & Hers has a market cap of $12.3 billion. You might think it's overvalued because of the stock's recent run-up in price, but the numbers show that patient investors could be rewarded by holding for the long term. A $12.3 billion market cap is only around 8 times my 2030 earnings estimate of $1.5 billion, which would be a dirt cheap price-to-earnings (P/E) ratio for a fast-growing company compared to the current market cap. Most likely, the stock will be valued at a higher multiple than 8, meaning that the stock will be higher in five years. It doesn't come without risks, but if you're a growth investor, you might love Hims & Hers stock for its long-term potential. Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Brett Schafer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Hims & Hers Stock Is Soaring Again. But Should You Buy the Stock? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
